The Life Sciences Report
Notable Quotes
"If ATHX can enroll a handful of Japanese patients to be part of the current phase 2 trial, that could create an accelerated pathway to the marketplace." (12/17/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"We'd love to see MSB launch a U.S. clinical trial with Prochymal in graft-versus-host disease, where an approved therapy is so desperately needed." (12/17/13) Mesoblast Ltd. - The Life Sciences Report Interview with Jason Kolbert More >
"When you think about the number of opportunities that exist for a company like INO, it's almost limitless." (12/17/13) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"CYTX operates its own subsidiary in Japan, and probably has the largest presence of any cell therapy company in that country." (12/17/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"I very much believe the results of NBS' trial will be positive." (12/17/13) NeoStem Inc. - The Life Sciences Report Interview with Jason Kolbert More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk Low: | ||
Tekmira Pharmaceuticals Inc.TICKER: TKMR:NASDAQ; TKM:TSX
|